SCHEMBL19013753

SCHEMBL19013753

Cn1cnc2c(=O)n(Cc3ccc(Cl)c(Cl)c3)c(=O)n(C)c21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
UBE2N P61088 1/20 0.50
STAT6 P42226 1/20 0.47
MAPT P10636 6/20 0.47
TP53 P04637 2/20 0.47
ALDH1A1 P00352 3/20 0.46
HIF1A Q16665 2/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 1/20 0.46
CYP2D6 P10635 1/20 0.45
MTHFD2 P13995 1/20 0.45
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23974900 0.83 ADORA3 (0.52) CYP3A4MAPTALDH1A1HIF1AHPGD
SCHEMBL18989514 0.81 MAPK1 (0.66) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL18989517 0.80 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL24554893 0.80 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL18991108 0.77 HSP90B1 (0.46) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL22471375 0.74 PDE4A (0.49) LMNACYP1A2CYP3A4
SCHEMBL18990403 0.74 PDE4A (0.57) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL23974903 0.73 PDE1A (0.49) SMN1; SMN2LMNACYP3A4ALDH1A1HIF1A
SCHEMBL18990418 0.72 ADORA2B (0.72) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL18990510 0.71 SMN1; SMN2 (0.69) SMN1; SMN2LMNAHTTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 US disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 SMN1; SMN2 1247/4885LMNA 3559/4885HTT 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.